Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors

Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors

Safety data on MET inhibitors in patients with advanced NSCLC harboring MET exon 14 mutation and treated with frontline immune checkpoint inhibitors (ICIs) are still limited. Here, we describe clinical characteristics, liver biopsy features, and management of liver injury of two patients with a diag...

Full description

Bibliographic Details
Main Authors: Monia Sisi, MD, Giovanni Vitale, MD, PhD, Michele Fusaroli, MD, Mattia Riefolo, MD, Valentina Giunchi, BSc, Antonietta D’Errico, MD, Andrea Ardizzoni, MD, Emanuel Raschi, MD, PhD, Francesco Gelsomino, MD
Format: Article
Language:English
Published: Elsevier 2023-09-01
Series:JTO Clinical and Research Reports
Subjects:
MET inhibitors
Immune checkpoint inhibitors
Liver toxicity
Drug-induced liver injury
FDA Adverse Event Reporting System
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364323001066

Internet

http://www.sciencedirect.com/science/article/pii/S2666364323001066

Similar Items